GlassScriptPhysician profile
Kinsleigh E Shah
NPI 1740934017
$4,430.67
in general payments reported to CMS, 2019-2025
27 companies · $974 in 2025
The $974 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,418 · 2023: $1,168 · 2024: $870 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.16 | 2022-2025 | |
| Genzyme Corporation | $514.47 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $499.67 | 2022-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $471.16 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $335.68 | 2022-2025 | Tremfya |
| Amgen INC. | $300.85 | 2022-2025 | Otezla, Enbrel |
| Leo Pharma INC. | $297.35 | 2022-2024 | Adbry |
| Ucb, INC. | $179.46 | 2022-2025 | Bimzelx |
| Pfizer INC. | $142.34 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.87 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $122.55 | 2023-2025 | |
| Incyte Corporation | $115.08 | 2022-2025 | Opzelura |
| Fresenius Kabi USA, LLC | $98.59 | 2023-2024 | Idacio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.73 | 2022-2023 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.16 | 2022-2025 | Spevigo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $66.47 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $57.80 | 2023 | |
| Organon LLC | $56.38 | 2024-2025 | Hadlima |
| Galderma Laboratories, L.P. | $56.29 | 2024-2025 | Nemluvio |
| Almirall LLC | $48.07 | 2022-2023 | Klisyri |
| Lilly USA, LLC | $36.13 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $35.40 | 2025 | Clindacin Etz |
| Kyowa Kirin, INC. | $16.85 | 2025 | |
| Sebela Pharmaceuticals INC. | $15.63 | 2023 | Naftin |
| Epi Health, LLC | $15.19 | 2022 | |
| Arcutis Biotherapeutics, INC. | $15.03 | 2023 | |
| Lnhc, INC | $14.31 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinsleigh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.